Medical News

RSS

Life Technologies, DKFZ collaborate to create National High-Throughput Sequencing Center

Life Technologies Corporation and the German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ) today announced their collaboration to create the National High-Throughput Sequencing Center. This exclusive partnership will create the largest sequencing facility in Germany and the first national sequencing center in Europe dedicated to systems biology.

3 Jun 2010

Case report on clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

3 Jun 2010

Biovail: BLS, Kyowa Hakko Kirin sign license agreement

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL, has entered into a license agreement with Kyowa Hakko Kirin Co., Ltd. BLS has acquired the U.S. and Canadian rights to commercialize products containing istradefylline - a new chemical entity targeted for the treatment of Parkinson's disease.

3 Jun 2010

Study: Shortened hospital stays may bring increased risks of return

"To save costs, hospitals for years have been discharging patients after shorter stays. But at the same time more people are having to return to hospital for additional care within a month of their initial treatment, according to a major new study of Medicare heart-failure patients."

3 Jun 2010

Medical marijuana hydroponics nutrients receive official US approval

In a landmark decision, Oregon regulators have given first-ever official US approval to a brand of medical marijuana hydroponics nutrients. Oregon and most other states have regulatory agencies that examine fertilizers and hydroponics plant supplements to determine the legitimacy, ingredients and effectiveness of plant growth products.

3 Jun 2010

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

GlaxoSmithKline today announced that it has received a letter from the U.S. Food and Drug Administration directing revisions to product labeling for its respiratory products Serevent and Advair. The letter concludes discussions between GSK and the agency following FDA advisory committee meetings regarding the safety profile of long-acting beta2-agonists in the treatment of asthma, including salmeterol, the active ingredient in Serevent and one of the active ingredients in Advair.

3 Jun 2010

Medtronic spent $1.07 million in first-quarter lobbying

Medical device giant Medtronic spent $1.07 million in the first quarter of the year to lobby Congress, including on health issues such as a provision of the new overhaul law that will extract up to $3 billion a year in fees from device makers, The Associated Press/Bloomberg Businessweek reports.

3 Jun 2010

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

MedImmune today announced that the U.S. Food and Drug Administration's Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus disease in high-risk infants.

3 Jun 2010

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

The National Institutes of Health has awarded scientists at Albert Einstein College of Medicine of Yeshiva University a five-year, $3.9 million grant to study how extensively drug-resistant tuberculosis is transmitted in rural South Africa. The findings could alter public health approaches for controlling the XDR-TB epidemic in the developing world.

3 Jun 2010

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.

3 Jun 2010

Beacon Partners study uncovers how healthcare organizations impacted by economy

Healthcare management consulting firm Beacon Partners recently conducted a study of healthcare executives nationwide resulting in over 200 responding to a survey uncovering how their healthcare organizations have been impacted by the economy.

3 Jun 2010

Loophole in CHIP costs feds millions in lost revenue

"A tobacco tax loophole in President Barack Obama's children's health insurance program cost the government more than $250 million in its first year, public health officials say. The loophole allowed companies to avoid huge tax increases on loose rolling tobacco by relabeling their product as pipe tobacco. The simple marketing twist lets companies pay $2.83 per pound, rather than the $24.78 per pound levied on rolling tobacco. That proved an expensive technicality in the way the government pays for health insurance for poor children."

3 Jun 2010

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, announced today that the company's highly selective oral kinase inhibitor, Telatinib, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of gastric cancer.

3 Jun 2010

NICE updates recommendations on diagnosis, treatment of low risk BCCs

The National Institute for Health and Clinical Excellence has updated its recommendations on the diagnosis and treatment of 'low risk' basal cell carcinomas.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

Same-sex partners to get long-term care benefits, federal personnel office says

Same-sex domestic partners of federal employees will next month be able to apply for long-term health insurance provided to government workers through the Office of Personnel Management, officials said Tuesday.

3 Jun 2010

NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed

Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.

3 Jun 2010

Middle-aged Americans are close to panic about future, says Alberta researcher

Middle-aged Canadians are much less worried about the future than their American counterparts, some of whom are close to panic, says an Alberta researcher who has just finished a survey in both countries. And she says the differing attitudes today may foreshadow growing differences between the two countries as that cohort move into old age.

3 Jun 2010

The Beryl Institute establishes grant program to improve patient experience in healthcare

As part of its commitment to support research and learning around customer service and the patient experience in healthcare, The Beryl Institute, based in Bedford, Texas, has established The Beryl Institute Patient Experience Grant Program.

3 Jun 2010

Researchers discover relationship between DNA methylation and positioning of nucleosomes

A previously unknown pattern in DNA methylation - an event that affects cell function by altering gene expression - has been uncovered for the first time by stem cell researchers at UCLA, a finding that could have implications in preventing some cancers and correcting defects in human stem cell lines.

3 Jun 2010

Medical News

Life Technologies, DKFZ collaborate to create National High-Throughput Sequencing Center

Case report on clear cell ICC

Biovail: BLS, Kyowa Hakko Kirin sign license agreement

Study: Shortened hospital stays may bring increased risks of return

Medical marijuana hydroponics nutrients receive official US approval

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

Medtronic spent $1.07 million in first-quarter lobbying

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Beacon Partners study uncovers how healthcare organizations impacted by economy

Loophole in CHIP costs feds millions in lost revenue

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

NICE updates recommendations on diagnosis, treatment of low risk BCCs

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Same-sex partners to get long-term care benefits, federal personnel office says

NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed

Middle-aged Americans are close to panic about future, says Alberta researcher

The Beryl Institute establishes grant program to improve patient experience in healthcare

Researchers discover relationship between DNA methylation and positioning of nucleosomes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News